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Abstract 
Objective 
To compare the Inhaler Compliance AssessmentTM (INCATM), a novel audio-recording 
device objectively measuring timing and proficiency of inhaler use, against established 
adherence measures, and explore its discriminant and predictive validity.  
Design 
Prospective observational study; 184 chronic obstructive pulmonary disease (COPD) patients 
used an INCATM-enabled salmeterol/fluticasone inhaler for one-month post-hospital 
discharge.  
Main Outcome Measures  
INCATM (Attempted, Attempted Interval, Actual) adherence correlated with Doses Used 
Rate, self-reported adherence and prescription refill for concurrent validity. Discriminant 
validity for reason for admission, cognition and lung function; predictive validity for health 
status and quality-of-life. 
Results 
Rates of Attempted, Attempted Interval and Actual adherence were 59%, 47% and 23%, 
respectively. Only 7% of participants had Actual adherence >80%.  INCATM variables 
significantly correlated with Doses Used Rate but not with self-report; Attempted and 
Attempted Interval were weakly associated with prescription refill. Higher cognitive and lung 
functioning groups had better INCATM adherence. Attempted and Attempted Interval 
predicted health status, while Doses Used Rate predicted quality-of-life.  
Conclusion 
INCATM did not strongly correlate with self-report or prescription refill data. Discriminant 
and predictive validity demonstrated by INCATM suggests the potential utility of the INCATM 
as a method to identify intentional and unintentional adherence to inhaled medication and 
facilitate targeted intervention.  
Key Words: chronic obstructive pulmonary disease (COPD); adherence; inhaler; electronic 
monitor; construct validity; predictive validity
Introduction 
Chronic Obstructive Pulmonary Disease: Symptoms, Prevalence, and Impact 
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory disease 
characterised by progressive airflow limitation and abnormal inflammatory response in the 
lungs (Rabe et al., 2007).  Predominant symptoms of the disease include dyspnoea, cough and 
sputum production, which cause considerable impairment in daily functioning and exercise 
capacity (Mewes, Rief, Kenn, Ried, & Stenzel, 2016). Global prevalence of COPD is 
projected to increase; such that by 2020, COPD is predicted to be the third leading cause of 
death, and fifth leading cause of disability worldwide (Lopez, Mathers, Ezzati, Jamison, & 
Murray, 2006). The chronic, progressive and debilitating nature of COPD, alongside its high 
prevalence, confers significant burden on the healthcare system (Bourbeau & Bartlett, 2008). 
Infections and other exposures cause a worsening of symptoms, leading to exacerbations. For 
example, respiratory diseases, including COPD, are the third most common indication for 
acute hospital admission in Ireland (Irish Thoracic Society, 2013). Aside from the costs 
incurred, repeated exacerbations impact both the clinical course of the disease and patient 
quality of life.  
Inhaler Adherence 
Although COPD cannot be cured, optimal management with inhaled bronchodilator therapy 
(including salmeterol-fluticasone) provides symptom relief, reduces exacerbations and slows 
disease progression; thereby, improving health-related quality of life (Bryant et al., 2013; 
Nannini, Cates, Lasserson, & Poole, 2007). However, treatment efficacy does not represent 
real-world effectiveness, and one of the major variables that may explain this gap concerns 
medication adherence. Medication adherence is defined as ‘the extent to which a patient acts 
in accordance with the prescribed interval and dose of a medication regimen’ (Cramer et al., 
2008). Adherence to inhaled medication has two major components: ‘temporal adherence’ 
(the deliberate initiation of medication use at the correct time and intervals) and ‘technique 
adherence’ (correct implementation) (Bryant et al., 2013; Holmes, D'Arcy, Costello, & 
Reilly, 2014). Suboptimal adherence may therefore arise from non-use, over-use or under-use 
(which could also be conceptualised as intentional non-adherence), or due to poor inhaler 
technique, forgetting or misunderstanding of the treatment regimen, factors which are not 
under conscious control of the individual (or unintentional non-adherence). Intentional non-
adherence may be driven by conscious decision-making processes in which individuals 
choose to limit, modify or cease treatment (DiMatteo, Haskard-Zolnierek, & Martin, 2012; 
Phillips, Cohen, Burns, Abrams, & Renninger, 2016).  
Estimates of adherence within COPD vary widely depending on the definitions and 
measures used, with reported rates of 70-90% in clinical drug trials and 20-60% in 
observational studies (Blackstock, ZuWallack, Nici, & Lareau, 2016; Di Martino et al., 
2014). Moreover, inhaler technique is poor among COPD patients (Bonini & Usmani, 2015).  
A recent systematic review demonstrated a significant association between non-
adherence to COPD medication and adverse outcomes including mortality, increased 
hospitalisations, impaired quality of life and reduced productivity (van Boven et al., 2014). 
Furthermore, studies have shown a significant association between non-adherence to 
salmeterol/fluticasone, as measured by the inhaler dose-counter, and increased hospital 
readmissions and mortality (Vestbo et al., 2009). 
Measuring Medication Adherence  
In order to improve medication adherence, it is vital to first assess it accurately. A 
challenge in doing this, however, concerns the lack of consensus between researchers and 
clinicians on which tools are most appropriate to quantify the extent of adherence (Lam & 
Fresco, 2015). Currently, there exist several ways to assess adherence to inhaled medications.  
The most common method is patient self-report whereby patients subjectively 
evaluate their own medication-taking behaviours. This can provide real-time feedback and 
identify individual concerns (Lam & Fresco, 2015). Although simple and inexpensive to 
administer, self-report has been shown to be susceptible to considerable reporting biases. 
Patients may under-report their level of non-adherence for a myriad of deliberate or 
accidental reasons (Lam & Fresco, 2015), including social desirability or recall biases.  
Alternatively, objective medication checks such as pharmacy reconciliation, 
prescription refill rates and drug counter checks are also used to quantify adherence (Lam & 
Fresco, 2015). These methods are useful tools for helping to predict future health care 
utilisation and costs (Karve et al., 2009; Sattler, Lee, & Perri, 2013). However, they are 
undermined by the assumption that refilling a medication corresponds to actual medication-
taking behaviour, and do not provide information about when or how medication is actually 
taken. Another simple objective method is the traditional dose-counter window on the side of 
an inhaler, which counts the number of doses taken by a participant. However, these methods 
do not capture important information on everyday inhaler use, from timing patterns to 
technique of use, or other aspects such as medication dumping. Consequently, these measures 
tend to overestimate adherence (Sulaiman et al., 2016; WHO, 2003).  
Electronic monitors address some of these limitations (Chan, Harrison, Black, 
Mitchell, & Foster, 2015). These monitors record the timing and frequency of inhaler drug 
administration, allowing for evaluation of drug taking patterns. For example, measurement 
from such devices is sometime disaggregated into indices of medication taking ‘initiation’, 
‘execution’ and ‘persistence’(Phillips et al., 2016).  However, simply opening a medication 
does not ensure its subsequent use or that it was taken correctly. These monitors do not 
capture time of use in conjunction with technique of use, which is essential for true drug 
delivery (Sulaiman et al., 2016).   
The limitations of the aforementioned adherence measures preclude their widespread 
utility as a gold standard for quantifying adherence. There is a need for a more sophisticated 
technology that can objectively measure both when and how an inhaler has been used, and 
discriminate between intentional and unintentional adherence. On the basis of this need, a 
novel device named the Inhaler Compliance AssessmentTM (INCATM) was developed. 
The Inhaler Compliance AssessmentTM 
The INCATM is a mobile technology audio recording device, fitted to a DiskusTM 
inhaler, comprising a small battery powered microphone, solid-state memory storage and a 
microprocessor (D'Arcy et al., 2014), see Figure 1. Opening the inhaler initiates an electronic 
acoustic file that records the audio associated with the inhalation. This recording terminates 
once the inhaler is closed. The audio files are time-stamped and stored on a memory platform 
until the device is uploaded to a PC. Subsequent processing and analysis of the audio files is 
conducted by an automated algorithm incorporating signal processing, with time-series 
analysis. This provides quantitative output information on technique, time, and duration of 
inhaler use (see Figure 2 for sample output). The audio recordings for the first 60 patients 
were over-read by two independent expert raters (observer agreement >80%), and the 
remaining patients’ audio files were over-read by a single expert-rater. This over-read data 
was subsequently used to calculate adherence. Detail on the sensitivity of the calculations and 
level of agreement between the two raters, and between the raters and the algorithm, have 
been previously published (Holmes et al., 2014; Holmes et al., 2013; Seheult, Costello, et al., 
2014; Seheult, O'Connell, et al., 2014). 
The acoustic data allows identification of each step of inhaler use and can therefore 
detect technique errors such as failure to prime the inhaler, dispersion of the medication by 
exhaling into the mouthpiece, low inhalation flow, dose dumping, and so on. In previous 
work, the accuracy of the INCATM algorithm for detecting technique errors has been 
validated in community dwelling asthmatic patients (Holmes et al., 2013) and against two 
expert human raters (Holmes et al., 2014), and with peak inspiratory flow, which correlates 
with the amount of drug delivered (D'Arcy et al., 2014; Seheult, Costello, et al., 2014; 
Seheult, O'Connell, et al., 2014). Therefore, output from the INCATM offers a precise and 
objective method of monitoring true drug delivery over time in an uncontrolled real-world 
environment, and can therefore distinguish intentional temporal non-adherence (e.g. Figure 
2(d)) from unintentional technique non-adherence (e.g. Figure 2(b)). However, no study yet 
has compared the INCATM with established measures of adherence, such as the inhaler dose-
counter, self-report or prescription refill.   
The Present Study 
The present study aims to evaluate the association among traditional medication 
adherence measures and INCATM estimates of adherence to bronchodilator therapy, 
specifically a salmeterol/fluticasone DiskusTM, in COPD. In particular, this project will firstly 
evaluate the concordance between adherence as measured by the INCATM, dose-counter, self-
report and prescription refill records to establish concurrent validity. Then, we explore the 
discriminant validity of the adherence measures for distinguishing known groups of clinical 
importance, and examine predictive validity of adherence measures for functional health 
outcomes (health status and disease-specific quality of life). 
 
Methodology 
Study Design and Procedure 
A prospective observational study design was used. The data analysed were collected 
as part of a broader, on-going research study investigating adherence to a regularly prescribed 
combination long acting beta-agonist/inhaled corticosteroid inhaler (salmeterol/fluticasone) 
by patients with COPD, following hospital discharge (Sulaiman et al., 2016). Between 
February 2012 and February 2016, data were collected in a large single-centre academic 
teaching hospital in [name withheld for peer-review]. 
Consecutive patients with an established diagnosis of COPD, already prescribed a 
salmeterol/fluticasone DiskusTM inhaler and admitted to hospital for any reason, were 
identified on the wards and screened by the investigator to determine eligibility. Exclusion 
criteria included residence in a nursing home and/or severe cognitive impairment (scores of 
less than 10 on the Montreal Cognitive Assessment (MoCA) (The Montreal Cognitive 
Assessment, 2009). At recruitment, consenting participants were provided with a new 60-
dose salmeterol/fluticasone DiskusTM inhaler fitted with an INCATM device, and completed a 
number of assessments with the investigator (duration approximately 20 minutes). Prior to 
discharge, participants were shown the correct use of their inhaler, and were asked to use it as 
demonstrated, twice per day at regular 12-hourly intervals, for the subsequent month. 
Participants were contacted by telephone at one-month (between 26 and 30 days following 
recruitment) to arrange collection of the inhaler via a courier. During this phone interview, 
participants also completed a number of follow-up assessments.  
Prescription refill adherence data for salmeterol/fluticasone and aspirin were collected 
retrospectively from the Health Services Executive Primary Care Reimbursement Scheme 
(HSE-PCRS). The HSE-PCRS is a pharmacy claims database detailing monthly dispensed 
medications for individuals on the General Medical Services (GMS) scheme (a means-tested 
scheme providing free health services and medication cover for eligible individuals in [name 
withheld for peer-review]). The study flow is illustrated in Figure 3. The [name withheld for 
peer-review] approved this study. 
Measures 
Socio-demographic Factors 
Socio-demographic information (including age, sex, body mass index (BMI) and 
smoking history) was collected during hospital admission. Data on level of social support was 
also recorded including access to public or private health insurance, living alone, having a 
carer and frailty factors (has a stair lift, has a bedroom downstairs, gets meals delivered or has 
a carer) (Sulaiman et al., 2016).  
Disease Severity Factors 
Data on pulmonary function [forced expiratory volume in one second (FEV1), as 
litres (L) and percentage predicted (%)], were extracted from the patients’ medical charts 
during hospital admission. Cough peak expiratory flow rate (PEFR; L/min) was measured at 
recruitment. Participants exhaled into a handheld device (Mini-Wright Clement Clarke 
International Ltd) with maximum force, from a sitting position and following a deep 
inhalation. Better lung function was indicated by a high PEFR. Peak inspiratory flow rate 
(PIFR), measuring the strength and speed exerted by an inhalation, was also measured at 
recruitment.  
Clinical and Treatment Characteristics 
Comorbid and mortality risk status was recorded using the Charlson Comorbidity 
Index, a measure of disease burden calculated by classifying co-morbid conditions and 
weighting them from one to six according to their adjusted risk of mortality. Scores range 
from 1-16, with scores greater than 8 indicating a high level of comorbidity (Charlson, 
Pompei, Ales, & MacKenzie, 1987). The RxRisk model, a pharmacy-based risk-assessment 
tool was retrospectively calculated from the HSE-PCRS database using an algorithm that 
groups prescription refills into chronic disease classes (Fishman et al., 2003).  
Information on cognitive function was also collected at baseline using the MoCA 
(Nasreddine et al., 2005), a 30-point assessment testing several cognitive domains including 
visuospatial/executive function, naming, attention, language, abstraction, delayed recall and 
orientation. The MoCA is a widely used screen for cognitive impairment with a 
recommended cut-off of <24 in the Irish population, (O'Caoimh, Timmons, & Molloy, 2016). 
At recruitment, data regarding treatment (including salmeterol/fluticasone dose, cause 
of admission, length of stay, number of nebulisers and medications prescribed) were retrieved 
from the patients’ medical charts. Prior to discharge, inhaler technique was also assessed 
through direct observation by the investigator using a 10-step checklist named the Inhaler 
Proficiency Scale (Mac Hale & Cowman, 2012). The IPS includes five items on correct 
handing and positioning of the inhaler, four items on correct inhalation and exhalation 
technique, and one item on gargling after use; these items were graded Yes/No based on 
correct execution.  
Adherence Measures 
INCATM Adherence. Analysis of the INCATM audio files by automated signal 
processing techniques provided information on timing of use and the interval between doses. 
Following this, data on time, interval between doses and technique were amalgamated to 
generate an area under the curve (AUC) metric, by a trapezoidal function; this method of 
adherence calculation has been previously described (Sulaiman et al., 2016). In brief, the 
AUC was calculated for participants’ Attempted adherence; that is, the number of times 
participants primed their inhaler and attempted to use it; Attempted Interval adherence; that 
is, evidence of drug priming at the correct intervals; and Actual adherence, which accounts 
for critical technique errors and is a measure of true medication delivery (incorporating 
intentional and unintentional nonadherence) (Sulaiman et al., 2016).   
Dose-Counter Adherence. The Doses Used Rate was calculated by reading the 
number of doses taken (out of a possible 60 doses) multiplied by 100.  
Self-reported Adherence. The Morisky Medication Adherence Scale (MMAS) 
(Morisky, Ang, Krousel-Wood, & Ward, 2008) is a widely-used 8-item scale used in the 
present study to measure self-reported adherence. The first 7 questions were answered with a 
dichotomous Yes/No response, while the final item was answered using a five-point Likert 
scale (ranging from ‘Rare/ never’ to ‘All of the time’). The MMAS total ranged from zero to 
8, where 8 indicated high self-reported adherence. The MMAS was further classified into 
high (score of 8), medium (score of 6 to <8) and low adherence (<6) as recommended 
(Morisky et al., 2008). The MMAS has demonstrated good reliability (Cronbach’s alpha= 
0.83), and using a cut-off of six, good sensitivity and specificity for identifying good and 
poor adherers (Morisky et al., 2008). In the present study, the MMAS was administered at 
one-month follow-up.  
Prescription Refill Adherence. Prescription refill adherence to salmeterol/fluticasone 
was retrospectively attained for a 12-month period prior to study enrolment for all 
participants holding a GMS card. Data on prescription refill adherence to oral aspirin was 
also obtained as a comparator drug, as most patients would be prescribed this as part of the 
COPD treatment regimen. Adherence rates were assessed using medication possession ratio 
(MPR) and proportion of days covered (PDC) calculations. MPR is a ratio of the proportion 
of doses obtained relative to the dispensing period (sum of days a medication is supplied over 
a set period, divided by the number of days in the period, multiplied by 100) (Karve et al., 
2009; Lam & Fresco, 2015). PDC is the accumulation of days the medication is available (or 
‘covered’) within a pre-determined observation period, divided by the number of days in that 
period, and multiplied by 100. MPR and PDC were used as continuous variables and also as 
dichotomised variables using ≥80% as a widely used cut-off between good and poor adherers 
(Karve et al., 2009; Sattler et al., 2013).  
Outcome Measures 
Health Status. The COPD Assessment Test (CAT) (Jones et al., 2009) was 
administered at baseline and one-month follow-up and is a patient-completed questionnaire 
measuring the global impact of COPD on health status. The questionnaire comprises 8 items 
assessing domains of disease severity (cough, sputum production, dyspnoea, and chest 
tightness) and impact on daily functioning (capacity for housework, confidence leaving the 
house, quality of sleep, and energy levels). Patients rated these items on a six-point scale 
(from one to five, e.g. zero ‘I never cough’ to five ‘I cough all the time’).  Total scores ranged 
from zero to 40, where higher scores were indicative of greater disease burden. The CAT has 
demonstrated excellent psychometric properties, including very good internal consistency 
(Cronbach’s alpha= 0.88) and test-retest reliability (intra-class correlation coefficient= 0.8) 
(Jones et al., 2009). 
Disease-Specific Quality of Life. The Medical Research Council (MRC) Dyspnoea 
scale (Fletcher, 1959) was also performed at baseline and follow-up and is a quick and easy 
to administer questionnaire grading the patients’ perceived disability associated with 
breathlessness. It comprises five statements and yields an ordinal score ranging from one ‘I 
only get breathless with strenuous exercise’ to five ‘I am too breathless to leave the house’. 
The MRC is widely used and has been shown to predict survival (Nishimura, Izumi, Tsukino, 
& Oga, 2002). 
Statistical Analysis 
Only participants with data available on both INCATM and prescription refill 
adherence measures were included in this analysis (n=184). Descriptive statistics were 
utilised to describe the demographic and clinical characteristics and adherence estimates. 
Continuous variables were summarised using means and standard deviations (S.D.), and 
medians and interquartile ranges (IQR) for non-normal or ordinal data. Frequencies and 
percentages are presented for categorical variables. For variables where the data were not 
normally distributed, a log transformation was conducted in order to achieve normality. 
Subsequent analyses were performed with this data on a log scale. For scores of zero, when a 
log transformation was not possible, a value of 0.01 was imputed. Concurrent validity was 
assessed using Pearson Product-Moment correlations for continuous variables, point biserial 
correlations for continuous and binary variables, and phi correlations for two binary 
variables.  A ‘known-groups’ approach (Hays, 1998) was employed to examine discriminant 
validity. A priori, groups were dichotomised cause of admission (COPD exacerbation, other 
reason); cognitive function (MoCA ≥ 24 normal, <24 cognitive impairment) and lung 
function (Cough PEFR ≥150 good, <150 poor). Post-hoc, we also assessed by smoking status 
(Yes/No), living alone (Yes/No), and having a carer (Yes/No). Independent samples t-tests 
assessed between-group differences on adherence variables. Finally, regression analyses 
predicted health outcomes at one-month follow-up. Continuous independent variables were 
standardised for ease of interpretation. Linear and ordinal regressions, adjusting for baseline 
CAT and baseline MRC, using robust variance estimators, predicted scores on the CAT and 
MRC respectively at follow-up. Data were analysed using Stata Version 10.0 (StataCorp, 
2007). 
 
Results 
Baseline Characteristics 
A total of 184 participants with data available on both INCATM and prescription refill 
adherence measures were included in this analysis (see Figure 3 for a consort diagram 
detailing study participation). Socio-demographic and clinical characteristics are provided in 
Table 1. In brief, participants were elderly with approximately half female. Eighty percent of 
participants had a GMS card. The sample had a mean pack years smoked of over 60 years, 
with a fifth still smoking. Participants had substantial COPD-related disability and 
impairment at baseline. In addition to their COPD, participants showed considerable burden 
of co-morbid conditions, and were prescribed a high number of regular medications. 
Adherence  
Adherence summary statistics are shown in Table 1. Using the AUC method for 
calculating INCATM adherence, the rate of Attempted adherence observed over the study 
period was 59%. When interval between doses was included, Attempted Interval adherence 
was 47%. Despite relatively good observer-rated inhaler technique at discharge (as per IPS 
checklist), once technique was incorporated into the adherence calculation alongside timing 
of use, the mean rate of Actual adherence was only 23%. Only 7% of participants had Actual 
adherence greater than 80%. Of the 60 doses expected over the follow-up period, the mean 
number of doses attempted, as measured by the dose-counter, was 46 doses. This corresponds 
to 77% of doses used.   
Approximately a third of participants self-reported reported a ‘high’ level of 
adherence, a further 46% reported ‘medium’ adherence and only a fifth reported ‘low’ 
adherence as per the MMAS.  
The mean MPRs for salmeterol/fluticasone and aspirin were 76% and 81%, 
respectively. Comparable PDC rates were observed, with 74% for salmeterol/fluticasone and 
81% for aspirin. Using 80% as a cut-off for good adherence, approximately 60% of 
participants demonstrated good MPR and 58% had good PDC adherence to their inhalers. No 
statistically significant differences between salmeterol/fluticasone and aspirin MPR rates (t 
(119) = -0.91, p= 0.364) or PDC rates (t (119) = -1.21, p= 0.230) were observed.  
Outcome Measures 
The means (S.D.) for health status (CAT) at baseline and one-month follow-up were 20.96 
(7.83) and 20.00 (8.07), respectively. The median (IQR) statistics for disease-specific quality 
of life, as measured by the MRC, were 4 (1) at baseline and similarly, 4 (1) at follow-up. 
Concurrent Validity  
Doses Used Rate, as measured from the inhaler dose-counter, was significantly 
strongly correlated with Attempted, Attempted Interval and INCATM adherence (Table 2). No 
significant correlations were observed between self-report and INCATM adherence variables. 
Attempted adherence was weakly correlated with MPR and PDC for salmeterol/fluticasone. 
Similarly, Attempted Interval adherence was weakly associated with salmeterol/fluticasone 
MPR and PDC. Actual adherence, however, was not significantly related to 
salmeterol/fluticasone MPR or PDC.  
Discriminant Validity 
A known-groups comparison approach was used to establish discriminant validity 
(see Table 3). Participants with normal or impaired cognitive function were observed to be 
significantly different on Attempted, Attempted Interval, Actual and Doses Used Rate 
adherence, with higher adherence for participants with normal cognitive function. No 
significant differences were observed between these participants on the self-report or 
prescription refill variables.  
In comparing lung function groups, participants with high and low Cough PEFR 
differed significantly on Attempted, Attempted Interval, and Actual adherence; that is, 
participants with higher Cough PEFR had correspondingly better INCATM adherence. No 
such differences were established between these participants on dose-counter, self-report or 
prescription refill adherence variables.  
Participants who reported living alone differed significantly on Attempted and 
Attempted Interval adherence, with poorer adherence observed for those living alone, as 
compared with their supported counterparts. No significant differences were observed 
between these participants on the self-report or prescription refill variables. 
No significant differences were observed between participants who: 1) were admitted 
for a COPD exacerbation or for another reason; 2) were still smoking at time of enrolment 
with those who had quit; or 3) had a carer, on any of the adherence measures.  
Predictive Validity  
Only INCATM Attempted and Attempted Interval adherence were predictors of health 
status (CAT) at follow-up, although these associations were weak (Table 4). In addition, the 
only significant predictor of disease-specific quality of life (MRC) was the Doses Used Rate 
(Table 5).  
Discussion  
This was a prospective observational study examining the concurrent, discriminant 
and predictive validity of the INCATM device, a novel objective adherence measure. INCATM 
Actual adherence was low, with only 7% of participants using their inhaler regularly and 
correctly greater than 80% of the time. In examining concurrent validity, we compared the 
INCATM to established measures of adherence, namely self-report and prescription refill. We 
found no association between INCATM and self-reported adherence, and small associations 
with adherence measured by prescription refill. Examination of discriminant and predictive 
validity showed the INCATM to have good clinical utility, in that the INCATM  was the only 
adherence measure to discriminate between good and poor adherence on important disease 
severity indicators, and to predict patient health status.    
Importantly, the INCATM was uniquely able to distinguish between intentional and 
unintentional adherence (arising from poor technique error). The discordance between 
INCATM Attempted and Actual adherence highlights the importance of examining technique 
(unintentional non-adherence) in conjunction with timing of use (intentional non-adherence). 
Analysis of the audio recordings from the INCATM device revealed that, in the month 
immediately following hospital discharge, both temporal and technique non-adherence to 
preventer inhaled therapy was common.  Less than 60% of patients attempted to use their 
inhaler, indicating a high rate of intentional non-adherence in this sample. Less than 50% 
attempted to use the inhaler at the correct time intervals, and once inhaler technique was 
incorporated, this figure dropped substantially to 23% actual adherence. Moreover, from a 
clinical perspective, only 7% of participants used their inhaler as prescribed more than 80% 
of the time, indicating a concerning rate of unintentional non-adherence. Despite repeated 
instruction on inhaler technique during admission, as per hospital policy, and despite good 
technique as measured by direct visual assessment (IPS checklist), poor technique was 
prevalent among this population once in an uncontrolled real-world environment. The 
considerably low level of actual adherence identified contrasts sharply with the high rates of 
adherence observed by other measures. For instance, the MPR and PDC rates of prescription 
refill adherence were high (76% and 81%, respectively). Moreover, the majority of 
participants subjectively reported a medium to high level of adherence, an unsurprising 
finding as self-report has been shown to consistently yield higher rates of adherence 
compared to objective measures (Berg & Arnsten, 2006). This discordance between 
adherence estimates by different measures highlights the limited real-world applicability of 
the previously established measures of adherence tested in this study, and highlights that the 
INCATM  is a superior measure of adherence than the others tested in this study.  
Using a known-groups approach, discriminant validity of the INCATM for clinically 
important features was established; good adherers had better cognitive and lung function than 
their poor adherer counterparts, and were more likely to live with others, which perhaps 
reflected increased social support. However, no significant differences were observed when 
comparing high or low MPR, PDC or self-report groups on these clinical and social 
characteristics. Interestingly, no significant differences on adherence were observed by 
smoking status. It may be that, in addition to the complexity of inhaler adherence, smoking 
cessation may be a complex behaviour to incorporate into a treatment regimen due to its 
addictive nature, and thus may be a recommendation only adhered to by a small proportion of 
the sample. Only the INCATM attempted variables were predictive of health status, and the 
Doses Used Rate predictive of disease-specific quality of life at follow-up, albeit weakly.  It 
is surprising that no association was observed for actual adherence and disease-specific 
quality of life, given the observed association between quality of life and Doses Used Rate. 
However, it may be that those with better health status represented those who were more 
clinically well and may have been better able to follow the instructions for correct inhaler 
use, and thus had higher quality of life at baseline assessment. It is important to note here that 
only 7% of the sample demonstrated actual adherence in terms of adequate delivery of the 
drug to the lungs, hence the observed associations are derived from a small sample.    
This study had a number of strengths. We examined a large COPD cohort in an 
uncontrolled real-world environment, and applied several measures of adherence, allowing 
for a comprehensive investigation of validity using one subjective and two objective 
measures. Additionally, this study measured adherence with a specifically developed 
objective adherence measure for inhalers. The INCATM is a novel adherence measure; 
capable of objectively monitoring patterns of intentional temporal and unintentional 
technique adherence in real-time. The incorporation of technique into the calculation of the 
Actual adherence allowed for a more comprehensive and accurate assessment of true 
medication delivery to be performed. In this way, the INCATM is a more sophisticated 
measure of adherence, improving upon some of the limitations of existing measures, i.e. the 
measurement of either timing or technique in isolation, reliance on patient self-report or 
examination of prescription refills.  
We acknowledge some methodological issues. Firstly, the present study was 
conducted in a single-centre, with the majority of patients on the GMS scheme; this may have 
favoured a lower socio-economic group. Varying socioeconomic status and education history 
have been shown to influence rates of adherence (Golay, 2011); possibly limiting 
generalisability. However, the high proportion of patients with government-sponsored health 
insurance may also be indicative of the cohort’s older age, disease-severity and high number 
of co-morbidities – clinical characteristics commonly observed in a COPD population. In 
addition, the INCATM examined medication adherence to only one pharmacological drug 
(salmeterol/fluticasone) using one method of administration (DiskusTM). However, this 
specific focus enabled a comprehensive investigation of adherence to a commonly prescribed 
COPD treatment. It could be argued that participants may have changed their inhaler use as a 
consequence of study enrolment, however previous examinations of a potential Hawthorne 
Effect (Williams, Amico, Bova, & Womack, 2013) in adherence studies have shown this not 
to be the case (Sutton et al., 2014).  
Whilst the INCATM, dose-counter and prescription refill measures provided data 
specifically on adherence to salmeterol/fluticasone, the items on the MMAS self-report scale 
weren’t specific to inhaler use and examined medication adherence more generally. These 
variations may have contributed to the paucity of, or weak, associations observed between 
INCATM and the self-report and prescription refill measures of adherence. However, aspirin 
was used as a comparator drug, as most participants were prescribed aspirin as part of their 
COPD medication regime and whilst the self-report measure used in this study did not 
specifically measure self-reported adherence to inhalers, there was no observed correlation 
between self-reported adherence and oral aspirin use, highlighting an overall lack of 
association between self-reported adherence and actual adherence. We acknowledge that the 
INCATM may not fully explore the extent to which non-adherence may be a consequence of 
forgetting to take medication, particularly when considering the level of cognitive impairment 
observed in this cohort. Notwithstanding, the INCATM is a potentially useful tool in the 
clinical setting for identifying and distinguishing volitional non-adherence from forgotten 
doses. The validity of self-reported adherence measures within cognitively impaired groups 
hasn’t been established (van Dulmen et al., 2007), therefore future research avenues should 
explore the utility of established measures of adherence amongst those with cognitive 
impairment. Although the sample demonstrated a number of comorbidities, only 6% of the 
sample had high-risk comorbidity scores on the Charlson Co-morbidity Index, therefore the 
sample was underpowered to investigate the impact of high vs. low comorbidity on 
adherence. This potential relationship should be considered in future research. Furthermore, 
future research should seek to explore patient- and healthcare professional- perspectives on 
the use of the INCATM, which may tease out patients’ perceptions of adherence to the 
treatment regimen and identify discrepancies with self-reported adherence. Finally, the 
duration of follow-up (one-month) may not have been sufficient to elicit substantial changes 
in health status and quality of life for the predictive validity analyses. Beliefs about value of 
the medication are meaningful predictors of non-adherence (DiMatteo et al., 2012) , and 
actual and perceived health status in the acute time period following a hospital admission 
may determine individual commitment to a complex treatment regimen, such as that in 
COPD (Phillips et al., 2016). Longer-term studies are required to more fully investigate the 
correlation between patient beliefs, INCATM adherence  and clinical parameters.  
The unique ability of the INCATM to objectively record temporal and technique 
adherence, alongside its significant association with peak inspiratory flow (D'Arcy et al., 
2014; Seheult, Costello, et al., 2014; Seheult, O'Connell, et al., 2014), demonstrates the 
potential utility of the INCATM as a reliable method for monitoring true medication delivery 
within a real-world context. Moreover, the accuracy of the INCATM for identifying 
intentional non-adherers, and technique errors, such as multiple inhalations, dose dumping, 
dispersion of the medication, and so on  (Holmes et al., 2014; Holmes et al., 2013), will help 
clinicians decide if a DiskusTM is an appropriate mode of drug delivery for a patient. 
Additionally, the discriminant and predictive validity of the INCATM is useful for identifying 
poor adherers and those at risk of adverse clinical outcomes. Individually tailored 
interventions are demonstrated to be superior to generic interventions in improving 
medication adherence (DiMatteo et al., 2012; van Dulmen et al., 2007). Personalised patient 
data from the INCATM serves as a platform from which to initiate tailored personalised 
conversations around behaviour change. Discussion of feedback can elicit technique errors, 
personal barriers to adherence or beliefs regarding the efficacy of the prescribed treatment 
regimen. This form of personalised feedback in turn allows for intervention using appropriate 
behaviour change techniques (Michie et al., 2013) to address individual barriers, such as goal 
setting to improve timing of treatment (Interval Adherence), increasing motivation and/or 
clarifying beliefs in the efficacy of treatment (Actual Adherence).  
 
Conclusion 
Inaccurate assessment of adherence has direct implications for the interpretation of the 
effectiveness of a treatment. The present study provides evidence for the use of  INCATM as a 
novel adherence assessor; capable of objectively monitoring patterns of intentional temporal 
and unintentional technique adherence in real-time. Based on our findings, we suggest that 
the INCATM is a more sophisticated measure of adherence, which improves upon some of the 
limitations of existing adherence measures, and has a potential useful role within clinical 
settings in the management of respiratory conditions.   
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 Tables 
Table 1. Baseline socio-demographic, disease severity, clinical, treatment and adherence 
characteristics.  
 
Variable Total Sample (N= 184) 
Socio-demographic Variables  
     Age, years: mean (S.D.) 70.9 (9.65) 
     Male, n (%) 95 (51.6%) 
     BMI, mean (S.D.) 27.5 (6.17) 
     Current smoker, n (%) 34 (20.4%) 
     Ever smoker, n (%) 168 (99.4%) 
     Pack years smoked, mean (S.D.) 60.8 (47.2) 
     Living alone, n (%) 43 (26.7%) 
     Has a carer, n (%)  41 (24.6%) 
     Frailty score, median (IQR) 2 (2) 
Disease Severity Variables  
     FEV1 (L), mean (S.D.) 1.33 (0.62) 
     FEV1 (%), mean (S.D.) 53.1 (21.7) 
     Cough PEFR (L/min), mean (S.D.) 160.9 (100.0) 
     Peak Inspiratory Flow, mean (S.D.) 71.7 (27.8) 
Clinical Characteristics  
     Charlson Co-morbidity, mean (S.D.) 5.92 (1.84) 
     RxRisk Adult, mean (S.D.) 5.35 (1.86) 
     MoCA, mean (S.D.) 21.5 (5.08) 
Treatment Factors  
     Dose Salmeterol/Fluticasone, n (%) 
           250mcg 
           500mcg 
 
40 (23.1%) 
133 (76.9%) 
     Cause of admission, n (%) 
           COPD exacerbation 
           Other  
 
114 (62.3%) 
69 (37.7%) 
     Length of stay, days: mean (S.D.) 7.72 (9.08%) 
     Number of prescribed medications, median (IQR) 15 (9) 
     Number of nebulisers used, median (IQR) 1 (2) 
     Smoking cessation treatment, n (%) 38 (20.7%) 
     Inhaler Proficiency Score, mean (S.D.) 7.64 (1.58) 
INCATM Adherence   
     INCATM Attempted, %: mean (S.D.) 58.7 (29.7) 
     INCATM Attempted Interval, %: mean (S.D.) 47.3 (33.4) 
     INCATM Actual, %: mean (S.D.) 23.2 (29.0)  
Doses Used Rate, %: mean (S.D.) 76.9 (28.9) 
Self-reported Adherence  (n= 83)  
     MMAS Total 1 Month FU, mean (S.D.) 6.75 (1.41) 
     MMAS Categories 1 Month FU, n (%) 
               High Adherence 
               Medium Adherence 
               Low Adherence 
 
29 (34.9%) 
38 (45.8%) 
16 (19.3%) 
Prescription Refill Adherence   
     MPR Salmeterol-Fluticasone, %: mean (S.D.) 75.6 (31.4) 
     PDC Salmeterol-Fluticasone, %: mean (S.D.) 73.8 (32.6) 
     MPR Aspirin (n= 122), %: mean (S.D.) 81.1 (29.6) 
     PDC Aspirin (n= 122), %: mean (S.D.) 80.5 (30.0) 
     ≥ 80% MPR Salmeterol-Fluticasone, n (%) 107 (59.8%) 
     ≥ 80% PDC Salmeterol-Fluticasone, n (%) 104 (58.1%) 
     ≥ 80% MPR Aspirin, n (%) 89 (73.0%) 
     ≥ 80% PDC Aspirin, n (%) 87 (71.3%) 
Baseline Outcome Measures  
     CAT, mean (S.D.) 20.9 (7.83) 
     MRC, median (IQR) 4 (1) 
Note. n, number of observations; S.D., standard deviation; BMI, body mass index; IQR, interquartile range; 
FEV1, forced expiratory volume in one second; L, litre; PEFR, peak expiratory flow rate;CAT, COPD 
Assessment Test; MRC; Medical Research Council; MoCA, Montreal Cognitive Assessment; mcg, micrograms; 
COPD, Chronic Obstructive Pulmonary Disease; MMAS, Morisky Medication Adherence Scale; FU, follow up; 
INCA, Inhaler Compliance Assessment; MPR, Medication Possession Ratio; PDC, Proportion of Days Covered. 
Table 2. Correlations between the adherence variables. 
 
Note. INCA, Inhaler Compliance Assessment; MMAS, Morisky Medication Adherence Scale; FU, follow up; MPR, Medication Possession Ratio; PDC, Proportion of Days 
Covered. 
a Point biserial correlation coefficient; b Phi correlation coefficient 
*Correlation is significant at the 0.05 level; **Correlation is significant at the 0.01 level; *** Correlation is significant at the 0.001 level
 1 2 3 4 5 6 7 8 9 10 11 12 
1. INCATM Attempted  -            
2. INCATM Attempted Interval  .85*** -           
3. INCATM Actual, Log10  .59*** .57*** -          
4. Doses Used Rate .55*** .57*** .38*** -         
5. MMAS Total 1 Month FU .07 .09 -.09 -.02 -        
6. MPR Salmeterol-fluticasone .15* .17* .05 0.10 -.11 -       
7.  PDC  Salmeterol-fluticasone .15* .16* .05 .10 -.11 .99*** -      
8.  MPR Aspirin -.04 -.03  -.13  -.02  -.21 .27** .26** -     
9.  PDC Aspirin  -.05  -.04  -.14  -.02  -.19 .26** .26** .99*** -    
10. ≥ 80% MPR Salmeterol- 
      Fluticasone 
.20a** .21a** -.01a .09a -.11a .86a*** .87a*** .21a* .21a* -   
11. ≥ 80% PDC Salmeterol- 
      Fluticasone 
.22a** .21a** .00a .09a -.08a .85a*** .86a*** .26a** .25a** .97b*** -  
12. ≥ 80% MPR Aspirin .01a .02a -.07a -.01a -.19a .19a* .19a* .86a*** .85a*** .18b .23b* - 
13. ≥ 80% PDC Aspirin .03a .03a -.07a -.02a -.19a .19a* .19a* .83a*** .84a*** .19b* .24b** .96b*** 
Table 3. Independent t-tests exploring the discriminant validity of the adherence measures using known-groups: a) Cause of admission; b) 
Cognitive function; c) Lung function; d) Smoking status; e) Living alone; f) Having a carer. Summary statistics are provided as Mean (Standard 
Deviation).  
 
 MMAS Total 
1 Month FU 
INCATM 
Attempted 
INCATM 
Attempted 
Interval 
INCATM 
Actual, 
Log10 
Doses Used  
Rate 
MPR 
Salmeterol/ 
Fluticasone 
PDC 
Salmeterol/  
Fluticasone 
Cause of Admission        
     COPD Exacerbation (n= 115) 6.96 (1.11) 61.1 (29.6) 49.9 (33.3) 0.91 (0.75) 77.5 (27.0) 73.9 (32.8) 71.7 (34.3) 
     Other Reason (n= 60) 6.50 (1.68) 53.2 (30.0) 41.5 (32.1) 0.84 (0.76) 74.7 (32.9) 79.4 (27.8) 78.3 (28.4) 
     p value .155 .097 .106 .553 .554 .288 .215 
Cognitive Function        
     Normal (n= 70) 6.36 (1.62) 67.9 (25.5) 57.5 (29.8) 1.11 (0.71) 83.8 (25.6) 73.4 (32.6) 71.3 (33.9) 
     Impairment (n= 105) 7.00 (1.32) 53.9 (31.2) 40.9 (34.4) 0.73 (0.74) 72.3 (30.0) 77.8 (29.7) 75.9 (31.1) 
     p value .071 .002** .001** .001*** .010** .362 .363 
Lung Function        
     High Cough PEFR (n= 75) 6.55 (1.09) 64.8 (27.5) 53.9 (31.4) 1.12 (0.73) 80.7 (28.1) 76.2 (29.5) 74.7 (30.3) 
     Low Cough PEFR (n= 78) 6.84 (1.61) 50.7 (30.1) 36.1 (32.1) 0.62 (0.68) 74.8 (29.3) 73.5 (32.9) 71.3 (34.7) 
     p value .411 .003** <.001*** <.001*** .204 .613 .526 
Current Smoker        
     Yes 6.45 (0.35) 51.5 (28.9) 39.7 (30.9) 0.78 (0.64) 80.9 (26.2) 68.8 (33.7) 66.4 (34.9) 
     No 6.86 (0.17) 60.8 (28.9) 49.3 (33.2) 0.92 (0.77) 77.0 (28.7) 77.1 (30.1) 75.6 (30.9) 
     p value .254 .098 .129 .317 .475 .168 .141 
Alone at Home        
    Yes 6.67 (1.58) 49.1 (30.3) 37.8 (32.2) 0.71 (0.72) 77.4 (30.7) 83.7 (25.6) 82.1 (26.2) 
    No 6.76 (1.35) 60.8 (27.7) 48.7 (32.6) 0.94 (0.75) 78.8 (27.3) 72.8 (31.8) 71.4 (32.7) 
     p value .799 .022* .0061** .081 .791 .054 .065 
Has a Carer        
    Yes 6.47 (2.09) 58.6 (29.8) 46.3 (33.5) 0.73 (0.69) 72.3 (30.5) 79 (27.9) 78.7 (27.7) 
     No 6.84 (1.07) 59 (29) 47.7 (33.3) 0.94 (0.75) 79.7 (27.3) 74.5 (32.1) 72.4 (33.3) 
     p value ..293 .925 .819 .125 .148 .431 .279 
Note. MMAS, Morisky Medication Adherence Scale; FU, follow-up; INCA, Inhaler Compliance Assessment; MPR, Medication Possession Ratio; PDC, Possession of Days 
Covered; COPD, Chronic Obstructive Pulmonary Disease; n, number of observations; PEFR, peak expiratory flow rate. 
*Significant at the 0.05 level; **significant at the 0.01 level; ***Significant at the 0.001 level 
Table 4. Linear regression models predicting scores on the CAT at one-month follow-up. 
Models are adjusted for baseline CAT score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. CAT, COPD Assessment Test; MMAS, Morisky Medication Adherence Scale; FU, follow up; INCA, 
Inhaler Compliance Assessment; MPR, Medication Possession Ratio; PDC, Proportion of Days Covered. 
Adjusted for baseline CAT.  
* Significant at the 0.05 level 
 
Model Number Variable R2 β 95% CI p value 
 INCATM Adherence     
1       INCATM Attempted  .21 -1.35 -2.62 to -.08 .038* 
2       INCATM Attempted Interval  .21 -1.32 -2.56 to -.07 .038* 
3       INCATM Actual, Log10 .19 -.78 -1.92 to .36 .180 
4 Doses Used Rate .19 -.78 -1.99 to .43 .204 
 Self-reported Adherence     
5      MMAS Total 1 Month FU .17 .11 -1.75 to 1.97 .904 
 Prescription Refill Adherence     
6      MPR Salmeterol/Fluticasone .19 -.43 -1.64 to .79 .488 
7      PDC Salmeterol/Fluticasone .19 -.36 -1.58 to .86 .560 
Table 5. Ordinal logistic regression models predicting scores on the MRC Dyspnoea scale at 
one-month follow-up. Models were adjusted for baseline MRC score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. MRC, Medical Research Council; MMAS, Morisky Medication Adherence Scale; FU, follow up; INCA, 
Inhaler Compliance Assessment; MPR, Medication Possession Ratio; PDC, Proportion of Days Covered. 
Adjusted for baseline MRC Dyspnoea score.  
* Significant at the 0.05 level
Model Number Variable Odds Ratio 95% CI p value 
 INCATM Adherence    
1       INCATM Attempted .77 .57 to 1.04 .093 
2       INCATM Attempted Interval  .81 .61 to 1.09 .164 
3       INCATM Actual, Log10 .92 .69 to 1.23 .586 
4 Doses Used Rate .72 .52 to .99 .043* 
 Self-reported Adherence    
5      MMAS Total 1 Month FU .82 .57 to 1.18 .279 
 Prescription Refill Adherence    
6      MPR Salmeterol/Fluticasone 1.05 .77 to 1.43 .768 
7      PDC Salmeterol/Fluticasone 1.05 .77 to 1.43 .735 
  
 
 
 
 
 
 
 
 
 
Figure 1. An image of a sample salmeterol/fluticasone DiskusTM inhaler fitted with an 
INCATM device (a). Opening the inhaler initiates an audio recording to be made (b). The 
INCATM is CE marked, and was designed at the Department of Bioengineering, Trinity 
College, the University of Dublin, Ireland and is manufactured by Vitalograph, Ennis, 
Ireland. 
  
  
Figure 2.  Patterns of inhaler technique shown by COPD patients in a preliminary study. 
Green dots indicate correct technique, and orange diamonds represent technique errors. In (a) 
the patient has the correct technique and takes the inhaler at the correct times, regularly 
interspersed at approximately 12-hourly intervals.  In (b) the patient uses the inhaler 
incorrectly but takes the inhaler at the correct times, regularly interspersed at approximately 
12-hourly intervals (i.e. unintentional nonadherence). In (c) the patient usually takes the 
inhaler correctly but only once a day. In (d) the patient rarely used their inhaler (i.e. 
intentional nonadherence).  
  
  
 
Figure 3.  Consort diagram detailing study participation. 
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